Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19-28z CAR EBV-VSTs
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
19-28z CAR EBV-VSTs is an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy developed by Memorial Sloan Kettering Cancer Center. The product utilizes Epstein-Barr virus (EBV)-specific T cells (EBV-VSTs) as a vehicle, which are genetically modified via gammaretroviral transduction to express a second-generation CAR targeting the CD19 antigen. This specific CAR construct, known as 19-28z, incorporates a CD28 costimulatory domain and a CD3-zeta signaling domain to enhance T-cell activation, proliferation, and persistence. By using EBV-VSTs derived from healthy donors, the therapy aims to reduce the risk of graft-versus-host disease (GVHD) and allows for the creation of a pre-manufactured cell bank, providing a readily available treatment for patients with relapsed or refractory B-cell malignancies without the delays associated with autologous manufacturing.
- Other names
- CD19-specific CAR EBV-VSTsCD-19-specific CAR EBV-VSTsCD 19-specific CAR EBV-VSTsAllogeneic CD19-targeted EBV-specific T cells19-28z CAR EBV-VST
02
Targets
Beyond the preview
Go deeper on 19-28z CAR EBV-VSTs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 19-28z CAR EBV-VSTs.